Redx agrees funding from Redmile Group, LLC & Sofinnova Partners

Redx agrees funding from Redmile Group, LLC & Sofinnova Partners

Redx Pharma PLC announced that Redmile Group, LLC, a large and well-funded US based specialist healthcare and life sciences investment firm, has confirmed to the Board that it, together with Sofinnova Partners – an active European life science institutional investor – will provide up to £26.3 million of funding to Redx.

Redmile has subscribed for 11.5m shares at 11.2p per share and will also provide short term debt financing of £5m.

Additionally, Redmile and Sofinnova Partners intend to invest £20m in the form of a convertible loan note.

The immediate subscription proceeds of £1.3 million for new ordinary shares will serve to extend cash runway until the end of April 2020 and will be used for general working capital purposes.

For the announcement click here

Important information

This information is of a general nature and does not constitute an offer to provide services.

The opinions and conclusions given here are those of Seneca Partners and are subject to change without notice.

The value of investments and/or any income arising from them may fluctuate.

Past performance is not necessarily a guide to future performance.

Important notice

The products and services shown on this website place capital at risk. Investors may receive less in returns than they have invested. Investments may not allow for capital to be withdrawn on demand. If an investment provides tax relief then this relief is subject to change and is dependant on personal circumstances. Any reference to past performance or forecasted performance is not a reliable indicator of future performance.

Seneca Partners recommends that any investor seeks specialised financial and/or tax advice before investing. Seneca Partners does not provide advice and the information on this website, including but not limited to news, should not be construed as such.

Please confirm that you understand this warning and wish to proceed.